2. Search Result
Search Result
Results for "

KB

" in MedChemExpress (MCE) Product Catalog:

2025

Inhibitors & Agonists

11

Screening Libraries

9

Fluorescent Dye

44

Biochemical Assay Reagents

103

Peptides

4

MCE Kits

31

Inhibitory Antibodies

862

Natural
Products

23

Recombinant Proteins

116

Isotope-Labeled Compounds

57

Antibodies

9

Click Chemistry

21

Oligonucleotides

3

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10257
    BAY 11-7085
    45+ Cited Publications

    BAY 11-7083

    		 NF-κB Ferroptosis Apoptosis Cancer
    BAY 11-7085 (BAY 11-7083) is an inhibitor of NF-κB activation and phosphorylation of IκBα; it stabilizes IκBα with an IC50 of 10 μM .
    BAY 11-7085
  • HY-P99207
    Lenzilumab
    1 Publications Verification

    KB 003

    		 SARS-CoV Cancer
    Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
    Lenzilumab
  • HY-137478
    KB-0742
    3 Publications Verification

    		 CDK Cancer
    KB-0742 is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity .
    KB-0742
  • HY-149461
    KB-05

    		Biochemical Assay Reagents Others
    KB-05 is an electrophilic fragment molecule that can be used in DIA-based quantitative chemical proteomic screening studies.
    KB-05
  • HY-15415
    KB-R7943 mesylate
    4 Publications Verification

    		 Na+/Ca2+ Exchanger Autophagy Cancer
    KB-R7943 mesylate is a widely used inhibitor of the reverse Na +/Ca 2+ exchanger (NCXrev) with IC50 of 5.7±2.1 μM. KB-R7943 mesylate induces cancer cell death via activating the JNK pathway and blocking autophagic flux.
    KB-R7943 mesylate
  • HY-76569
    Desfesoterodine
    1 Publications Verification

    PNU-200577; 5-Hydroxymethyl Tolterodine

    		 mAChR Neurological Disease Cancer
    Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .
    Desfesoterodine
  • HY-12170
    Prinomastat
    4 Publications Verification

    AG3340; KB-R9896

    		 MMP Apoptosis Cancer
    Prinomastat (AG3340) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. Prinomastat inhibits MMP-2, MMP-3, MMP-13 and MMP-9 with Kis of 0.05 nM, 0.3 nM, 0.03 nM and 0.26 nM, respectively. Prinomastat crosses blood-brain barrier. Antitumor avtivity .
    Prinomastat
  • HY-137478A
    KB-0742 dihydrochloride
    3 Publications Verification

    		 CDK Cancer
    KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .
    KB-0742 dihydrochloride
  • HY-142069
    KB-R7785

    		MMP Neurological Disease Metabolic Disease
    KB-R7785 is a matrix metalloproteinase (MMP) inhibitor, which improves insulin sensitivity by inhibiting TNF-α production. KB-R7785 can be used for diabetes research. KB-R7785 has a protective efficacy against focal cerebral ischemia .
    KB-R7785
  • HY-15573
    EI1
    2 Publications Verification

    KB-145943

    		 Histone Methyltransferase Apoptosis Cancer
    EI1 (KB-145943) is a potent and selective EZH2 inhibitor with IC50 of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.
    EI1
  • HY-10473
    Eprotirome

    KB2115

    		 Thyroid Hormone Receptor Metabolic Disease Endocrinology
    Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .
    Eprotirome
  • HY-15528
    kb NB 142-70
    2 Publications Verification

    		 PKD Cancer
    kb NB 142-70 is a potent PKD inhibitor, with IC50s of 28.3, 58.7 and 53.2 nM for PKD1, PKD2, and PKD3, respectively. kb NB 142-70 also has antitumor activity.
    kb NB 142-70
  • HY-177554
    KB05yne

    		Biochemical Assay Reagents Cancer
    KB05yne is a site-selective, alkyne-functionalized electrophilic "probe" fragment probe designed for covalent ligand discovery, with preferential reactivity toward specific cysteine residues in proteins. KB05yne strongly labels wild-type target proteins (e.g., CDKN2AIP, HPCAL1) but does not label their cysteine-to-alanine mutants, confirming site-specific cysteine reactivity. KB05yne can be used for the discovery and optimization of site-specific covalent ligands, and is applicable to proteins with diverse structures and functions, especially in studies targeting cysteine residues in cancer-related or difficult-to-purify proteins .
    KB05yne
  • HY-P3333
    KSPWFTTL

    		MHC Inflammation/Immunology Cancer
    KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .
    KSPWFTTL
  • HY-N2815
    Ursolic acid acetate

    Acetylursolic acid; 3-Acetylursolic acid

    		 Parasite HSP Infection Cancer
    Ursolic acid acetate (Acetylursolic acid) is a triterpenoid compound and an inhibitor of Plasmodium falciparum heat shock protein 90 (PfHsp90) with a KD of 8.16 μM. Ursolic acid acetate is cytotoxic to KB cells, with an IC50 value of 8.4 μM. Ursolic acid acetate can be used in tumor and antimalarial research .
    Ursolic acid acetate
  • HY-B0768A
    Lomerizine dihydrochloride
    1 Publications Verification

    KB-2796

    		 Calcium Channel Neurological Disease
    Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.
    Lomerizine dihydrochloride
  • HY-N2132
    Flavokawain B
    2 Publications Verification

    Flavokavain B

    		 Apoptosis Caspase PARP Bcl-2 Family NF-κB PI3K Akt p38 MAPK MMP Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology Cancer
    Flavokawain B (Flavokavain B) is an orally active chalcone. Flavokawain B results in activation of caspase-9, -3 and -8, cleavage of PARP. Flavokawain B down-regulates Bcl-2 with concomitant increase in Bax level. Flavokawain B inhibits NF-κB, PI3K/Akt and MAPK signaling pathway. Flavokawain B exhibits Apoptotic effects. Flavokawain B inhibits MMP-9 and promotes ROS generation. Flavokawain B inhibits multiple tumors and inflammation .
    Flavokawain B
  • HY-131385
    KB02-COOH

    		Ligands for E3 Ligase Cancer
    KB02-COOH is a fragment of synthesis of ubiquitin E3 ligase ligand KB02. KB02 can be used in the synthesis of PROTAC, such as KB02-JQ1 (HY-129917) and KB02-SLF (HY-129610) .
    KB02-COOH
  • HY-129610
    KB02-SLF

    		PROTACs FKBP Cancer
    KB02-SLF is a PROTAC-based nuclear FKBP12 degrader (molecular glue). KB02-SLF promotes nuclear FKBP12 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF .
    KB02-SLF
  • HY-129917
    KB02-JQ1
    4 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1 .
    KB02-JQ1
  • HY-12170A
    Prinomastat hydrochloride
    4 Publications Verification

    AG3340 hydrochloride; KB-R9896 hydrochloride

    		 MMP Apoptosis Cancer
    Prinomastat hydrochloride (AG3340 hydrochloride) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. Prinomastat hydrochloride inhibits MMP-2, MMP-3, MMP-13 and MMP-9 with Kis of 0.05 nM, 0.3 nM, 0.03 nM and 0.26 nM, respectively. Prinomastat hydrochloride can cross blood-brain barrier. Antitumor avtivity .
    Prinomastat hydrochloride
  • HY-76574
    3-(Trifluoromethyl)benzaldehyde

    		Drug Intermediate Cancer
    3-(Trifluoromethyl)benzaldehyde is a key intermediate in organic synthesis. 3-(Trifluoromethyl)benzaldehyde can be used to synthesize 2,3-di- and 2,2,3-trisubstituted-3-methoxycarbonyl-γ-butyrolactones .
    3-(Trifluoromethyl)benzaldehyde
  • HY-155998
    NF-κB-IN-11
    1 Publications Verification

    		 NF-κB Inflammation/Immunology
    NF-κB-IN-11 (Compound 3i) is a NF-κB inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .
    NF-κB-IN-11
  • HY-138537
    NF-κB-IN-1
    3 Publications Verification

    		 IKK Cancer
    NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells .
    NF-κB-IN-1
  • HY-136741
    BOT-64
    2 Publications Verification

    		 IKK Inflammation/Immunology
    BOT-64 is an inhibitory κB (IκB) kinase β (IKKβ) inhibitor with an IC50 of 1 µM. BOT-64 blocks lipopolysaccharide-induced nuclear factor-κB activation and nuclear factor-κB-regulated inflammatory gene transcription .
    BOT-64
  • HY-174138
    NF-κB degrader 1

    		NF-κB Inflammation/Immunology
    NF-κB degrader 1 (Compound MD-1) is a NF-κB1 p105 subunit degrader. NF-κB degrader 1 shows anti-inflammatory activity (IC50 for inhibiting TNF-α is 2.02 μM, and for inhibiting NO is 5.40 μM). NF-κB degrader 1 induces p105 degradation dependent on the Cullin-RING ligase (CRL) SCFBTCP, suppressing NF-κB transcriptional activity. NF-κB degrader 1 is promising for research of inflammation-related diseases .
    NF-κB degrader 1
  • HY-120026
    KB130015
    1 Publications Verification

    KB015

    		 Thyroid Hormone Receptor Calcium Channel Potassium Channel Sodium Channel Cardiovascular Disease
    KB130015 (KB015) is an orally active and potent ThRα and ThRβ (thyroid hormone receptor) inhibitor, with IC50 values of 4.5 and 5.1 μM, respectively. KB130015 markedly slows the kinetics of inactivation of Na + channels. KB130015 activates hERG1 channels (EC50 = 12.2 μM) and large-conductance Ca 2+-activated K + (BKCa) channels formed by hSlo1 (α) subunits in HEK 293 cells. KB130015 has antiarrhythmic properties. KB130015 can be used for the study of cardiovascular disease .
    KB130015
  • HY-108488
    KB SRC 4

    		Src Cancer
    KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.
    KB SRC 4
  • HY-130082
    DM4-SMe

    		ADC Payload Microtubule/Tubulin Cancer
    DM4-SMe is a metabolite of antibody-maytansin conjugates (AMCs) and a tubulin inhibitor, and also a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an IC50 of 0.026 nM. DM4-SMe is a highly toxic metabolite that can be oxidized and detoxified by human liver microsomes .
    DM4-SMe
  • HY-170506
    KB-208

    		Thrombopoietin Receptor Inflammation/Immunology
    KB-208 is a phagocytosis inhibitor that acts similarly to intravenous immunoglobulin (IVIG). KB-208 improves immune thrombocytopenia (ITP) in a mouse model at a dose of 1 mg/kg. KB-208 does not affect other blood parameters and does not elevate serum biochemical markers of toxicity, and can be used in research in the field of immunity .
    KB-208
  • HY-144765
    NF-κB-IN-4
    1 Publications Verification

    		 NF-κB Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    NF-κB-IN-4 (compound 17) is a potent NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
    NF-κB-IN-4
  • HY-P99135
    Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3)

    		MHC Inflammation/Immunology
    Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) is a mouse-derived IgG2b antibody inhibitor, targeting to mouse MHC Class I (H-2Kb). Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) reacts with the mouse H-2Kb, H-2Kk, H-2Kq, H-2Kr, H-2ks MHC class I alloantigens and not H-2Kd. Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) can block MHC Class I. Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3) can be used for immunology research .
    Anti-Mouse MHC Class I (H-2Kb) Antibody (Y-3)
  • HY-P99953
    Rivabazumab

    KB001

    		 Bacterial Infection
    Rivabazumab is a recombinant antibody against Pseudomonas aeruginosa pcrV .
    Rivabazumab
  • HY-117167
    KB-141

    		Thyroid Hormone Receptor Cancer
    KB-141 is a potent and selective TRβ agonist. The IC50 values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .
    KB-141
  • HY-16698
    kb-NB77-78

    		PKD Cancer
    kb-NB77-78 is an analogue of CID797718, but shows no PKD inhibitory activity .
    kb-NB77-78
  • HY-RS22402
    Axin1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Axin1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Axin1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Axin1 Mouse Pre-designed siRNA Set A
    Axin1 Mouse Pre-designed siRNA Set A
  • HY-P3333A
    KSPWFTTL TFA

    		MHC Inflammation/Immunology Cancer
    KSPWFTTL TFA is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL TFA can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes .
    KSPWFTTL TFA
  • HY-N15199
    Schisanlactone A

    		Others Cancer
    Schisanlactone A is a natural triterpenoid compound. Schisanlactone A has moderate cytotoxicity, with its IC50 value being 63.3 μM against KB cells. Schisanlactone A does not possess antibacterial or tyrosinase inhibitory activities. Schisanlactone A can be used for the study of oral epidermoid carcinoma .
    Schisanlactone A
  • HY-168482
    NF-κB/MAPK-IN-2

    		NF-κB p38 MAPK Cancer
    NF-κB/MAPK-IN-2 (compound 14) is a potent NF-κB and MAPK Inhibitor. NF-κB/MAPK-IN-2 decreases the protein expression of p-p65, p-IκB, p-p38, p-JNK, and p-ERK. NF-κB/MAPK-IN-2 reduces the LPS-induced release of TNF-α and IL-6. NF-κB/MAPK-IN-2 inhibits nuclear translocation of p65 and c-Fos. NF-κB/MAPK-IN-2 has the potential for the research of sepsis .
    NF-κB/MAPK-IN-2
  • HY-137478B
    KB-0742 hydrochloride

    		CDK Cancer
    KB-0742 hydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 hydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 hydrochloride has potent anti-tumor activity .
    KB-0742 hydrochloride
  • HY-W681659
    Flutoprazepam

    KB-509

    		 GABA Receptor Neurological Disease
    Flutoprazepam (KB-509), a benzodiazepine drug, possesses anticonflict effect. Flutoprazepam (KB-509) prevents maximal electroshock, pentetrazol, and strychnine-induced convulsions in mice .
    Flutoprazepam
  • HY-176535
    KB-0118

    BBC0115

    		 Epigenetic Reader Domain Interleukin Related STAT Inflammation/Immunology
    KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with Kd values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model.
    KB-0118
  • HY-147196
    KB03-SLF

    		PROTACs FKBP Cancer
    KB03-SLF (compound 6) is an electrophilic PROTAC degrader that binds to DCAF16 to degrade the nuclear protein FKBP12. KB03-SLF can be used in cancer research . (Pink: Ligand for target protein SLF (HY-114872); Black: Linker (HY-W040168); Blue: Ligand for E3 ligase (HY-169968)).
    KB03-SLF
  • HY-47228
    KB-5492 free base

    		Sigma Receptor Inflammation/Immunology
    KB-5492 free base is a potent and selective inhibitor of sigma receptor, inhibits specific [ 3H]1,3-di(2-tolyl)guanidine (DTG) binding to the sigma receptor with an IC50 of 3.15 μM. KB-5492 free base is an anti-ulcer agent .
    KB-5492 free base
  • HY-176389
    KB02-amide-PEG2-C2-acid

    		E3 Ligase Ligand-Linker Conjugates Cancer
    KB02-amide-PEG2-C2-acid is a synthesized E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs, such as KB02-SLF (HY-129610) .
    KB02-amide-PEG2-C2-acid
  • HY-76569R
    Desfesoterodine (Standard)

    PNU-200577 (Standard); 5-Hydroxymethyl Tolterodine (Standard)

    		 Reference Standards mAChR Neurological Disease
    Desfesoterodine (Standard) is the analytical standard of Desfesoterodine. This product is intended for research and analytical applications. Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively . Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053) . Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats .
    Desfesoterodine (Standard)
  • HY-126640
    Phomoxanthone A

    		Parasite Infection Cancer
    Phomoxanthone A is a xanthone dimer, which can be isolated from Phomopsis. Phomoxanthone A exhibits antimalarial and antitubercular activities against Plasmodium falciparum (K1, multidrug-resistant strain, IC50 is 0.11 µg/mL) and Mycobacterium tuberculosis (H37Ra strain, MIC is 0.50 µg/mL). Phomoxanthone A exhibits cytotoxicity in cells KB, BC-1 and Vero, IC50 is 0.99, 0.51 and 1.4 µg/mL, respectively .
    Phomoxanthone A
  • HY-144744
    NF-κB-IN-3

    		NF-κB Cancer
    NF-κB-IN-3 (Compound 2) is a NF-κB inhibitor with an IC50 of 0.70 µM. NF-κB-IN-3 can be used as an antitumor agent .
    NF-κB-IN-3
  • HY-105449A
    KB R6933

    KB 6806 maleate

    		 5-HT Receptor Cardiovascular Disease
    KB R6933 (KB 6806 maleate) is a potent, selective and orally active 5-HT3 receptor antagonist. KB R6933 can inhibit the diarrhea induced by 5-HT (HY-B1473A), but not that by Castor Oil (HY-107799) or prostaglandin E2 (PGE2) (HY-101952). KB R6933 can inhibit 5-HT-induced bradycardia .
    KB R6933
  • HY-175542
    KB-15

    		STAT Apoptosis Reactive Oxygen Species (ROS) PARP Cancer
    KB-15 is a STAT3 inhibitor. KB-15 exhibits potent anti-proliferative activity against AGS gastric cancer cells (IC50 = 0.29 μM) and BGC-823 gastric cancer cells (IC50 = 0.65 μM). KB-15 exerts anti-tumor effects by inhibiting STAT3 phosphorylation, downregulating HO-1 expression, and promoting intracellular ROS accumulation. KB-15 induces G0/G1 phase cell cycle arrest and apoptosis, as well as suppresses colony formation and migration of gastric cancer cells. KB-15 demonstrates excellent anti-tumor efficacy in BGC-823 subcutaneous xenograft model. KB-15 can be used for the study of gastric cancer .
    KB-15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: